Clinical stage CNS biopharmaceutical company developing novel therapies that initiate new neuron growth to reverse rare pediatric (e.g., Fragile X syndrome) and age-related neuron degenerative disorders (e.g., Alzheimer's, Parkinson's and Canine Cognitive disorder). Unique MOAs due to original phenotypic screening platform to discover safe, BBB permeable and neuron generating/protecting small molecules. Positive Phase1a and prepared for Phase2.